There is a body of human research on molecular hydrogen and kidney failure that most hydrogen marketing never mentions, and there is a good reason for the silence: none of it involves drinking anything.
In this literature, hydrogen is dissolved into the dialysate, the fluid that runs on the other side of the membrane in a dialysis machine, and it reaches the patient by diffusing across that membrane into the blood circuit. It is delivered by a hospital machine, at concentrations measured in parts per billion, during a treatment session. There is no tablet, no bottle and no consumer product anywhere in it.
That distinction is the whole point of this page. The dialysis research is some of the longest-running human work on molecular hydrogen anywhere, and it is genuinely interesting. It also transfers to a home hydrogen tablet almost not at all.
Where the idea came from
People on long-term dialysis live with elevated oxidative stress, and the dialysis session itself contributes to it, because blood is in sustained contact with an artificial membrane. Chronic inflammation in dialysis patients is associated with poor prognosis, and the therapeutic options for it are limited[1]. That is the gap this work was aiming at.
The starting observation was chemical rather than clinical. Water electrolysed on the cathode side carries dissolved hydrogen and shows less oxidative capacity in chemical terms than ordinary water. When researchers used it to make reverse osmosis water and then dialysis solution, the resulting solution had measurably lower oxidative capacity than a control solution, and higher dissolved hydrogen levels[2].
They then tested what it did to cells. Human polymorphonuclear leukocytes, a type of white blood cell, were better protected against injury when exposed to the electrolysed-water-based solution[2]. A follow-up study reported that basal cell viability and the cells’ capacity to generate superoxide radicals were better preserved[3].
The first patients
The same 2009 report included a small feasibility test in people. Dialysis using the electrolysed reverse osmosis water was performed for 12 consecutive sessions in 8 patients[3].
Reductions in blood pressure were noted and no adverse events were observed. Standard blood dialysis parameters did not change, though methylguanidine levels, a uraemic marker, fell significantly by the end of the study[3].
Eight patients over twelve sessions is a feasibility test, not evidence of benefit. Its job was to establish that the technique could be run safely on real patients, and it did that.
The six-month trial
The most substantial human study is a 2010 clinical trial. Dialysis solution containing an average of 48 parts per billion of dissolved hydrogen was produced by mixing dialysate concentrates with reverse osmosis water carrying electrolytically generated hydrogen. 21 stable patients on standard dialysis were switched to the test system for 6 months, at three sessions a week[1].
The results, as reported: no adverse clinical signs or symptoms across the study period. A significant decrease in systolic blood pressure before and after dialysis. The proportion of patients achieving a post-dialysis systolic pressure below 140 millimetres of mercury rose from 21 percent at baseline to 62 percent at 6 months, significant at p less than 0.05. Plasma monocyte chemoattractant protein 1 fell significantly at p less than 0.01, and myeloperoxidase fell significantly at p less than 0.05, both of them inflammation markers. Changes in dialysis parameters were minimal[1].
The authors concluded that adding hydrogen to the dialysis solution ameliorated inflammatory reactions and improved blood pressure control[1].
What that trial did not have
It had no control group. Twenty-one patients were switched from their usual treatment to the test treatment and were compared against their own baseline. There was no placebo arm and no parallel group continuing on standard dialysis.
That matters more than it might sound. Blood pressure in dialysis patients is actively managed, drifts with fluid status and dry weight, and responds to clinical attention. Twenty-one patients enrolled in a study and watched closely for six months would be expected to see some blood pressure improvement regardless of what was in the dialysate. A before-and-after design cannot separate the hydrogen from everything else that happened over those six months.
This is not a reason to dismiss the finding. It is a reason to hold it as a promising uncontrolled observation rather than as a demonstrated effect, which is what an uncontrolled study can support.
The one crossover study
The design problem above was partly addressed by a later study that did use a crossover. Eight patients on regular dialysis each underwent two sessions, one with standard solution and one with a hydrogen-enriched solution averaging 50 parts per billion[4].
Blood was sampled at the inlet and outlet of the dialyzer to measure what the pass through the machine did. In both treatments, total and reduced glutathione fell significantly and hydrogen peroxide rose significantly between inlet and outlet, which is the expected oxidative signature of a dialysis pass. But the proportion of reversibly oxidised albumin in the outlet was significantly lower than in the inlet after the hydrogen session, while no significant change appeared in the standard session[4].
The authors read that as evidence that oxidative stress occurring inside the dialyzer is reduced by the hydrogen-enriched solution[4]. It is a small study, eight people, and its endpoint is a blood chemistry marker rather than anything a patient would feel. But it is a within-person comparison against a proper control condition, which makes it the cleanest piece of evidence in this whole area.
Why hydrogen rather than another antioxidant
The mechanistic argument is the same one that underpins the rest of the hydrogen literature. Molecular hydrogen reacts preferentially with hydroxyl radical, the most damaging of the reactive oxygen species, while leaving physiologically useful radicals such as superoxide and nitric oxide comparatively alone[5]. That selectivity is the reason it was proposed as a therapeutic gas rather than as another broad-spectrum antioxidant[6].
Hydrogen also passes membranes freely, which is why dissolving it in dialysate works at all. A conventional antioxidant added to dialysate would have to cross the dialysis membrane on its own terms and would carry a dose and a clearance profile. Hydrogen diffuses.
There is a second, more speculative line. An in-vitro study using simulated dialysis found that dialysate with high dissolved hydrogen significantly improved the dissociation of indoxyl sulfate from albumin, at p less than 0.05[7]. Indoxyl sulfate is a protein-bound uraemic toxin that conventional dialysis removes poorly. If that held up in people, it would be a mechanism with nothing to do with antioxidant effects at all. It has not been shown in people, and the study was performed on concentrated waste dialysate in a laboratory circuit.
The peritoneal dialysis branch
A parallel line of work targets peritoneal dialysis, where the patient’s own peritoneal membrane does the filtering. Membrane failure is a critical reason patients have to stop peritoneal dialysis, so preserving the membrane is a real clinical goal.
In rats given peritoneal dialysis solution with dissolved hydrogen at 400 parts per billion for 10 days, there was significantly less sub-mesothelial thickening and significantly fewer apoptotic, proliferating and vimentin-positive cells than in rats given standard solution[8]. A later report in rats with experimental chronic kidney disease found a significant increase in mesothelial cell numbers and a significant decrease in peritoneal thickness in the hydrogen group[9].
Those are rat studies. The human component so far is a 2-week clinical trial in 6 prevalent peritoneal dialysis patients. All 6 completed with no adverse effects, and there were substantial changes in effluent markers such as CA125 and mesothelin in selected cases, which the authors suggest may indicate enhanced mesothelial regeneration[9].
Six patients, two weeks, surrogate markers, changes in selected cases. The authors describe it as supporting the case for future trials, which is the correct weight to give it.
The finding that limits the whole idea
A 2025 study measured where the hydrogen actually goes, using a new direct-dissolution system in a canine dialysis model. It maintained high and stable concentrations, roughly 1,600 parts per billion in the reverse osmosis water and around 230 parts per billion in the final dialysate, and hydrogen diffused efficiently into the blood circuit, with outlet concentrations reaching 54.0 to 67.7 percent of the dialysate level[10].
Then it measured arterial blood. Systemic arterial concentrations at the pulmonary and carotid arteries were low, indicating significant pulmonary clearance. The authors concluded that hydrogen delivered this way acts primarily locally, within the circuit and the dialyzer, rather than systemically[10].
That is an honest and important result, and it points in a specific direction. If hydrogen delivered through a dialysis machine is largely breathed out before it circulates, then the plausible benefit is protecting blood during its pass through the machine, which is exactly what the albumin redox crossover study measured. Claims about system-wide antioxidant effects in dialysis patients do not follow from this delivery route. The authors suggest haemodiafiltration as a way to improve systemic delivery, which is a proposal for future work, not a finding.
Who is behind this research
This literature comes from a small number of groups, and it has industry involvement that a reader should know about.
A 2024 review of electrolysed hydrogen water for chronic kidney disease and dialysis carries a conflict of interest statement in which the lead author declares honoraria for speaking at symposia from Nihon Trim Co., Ltd. and a position on that company’s advisory boards, and a second author is disclosed as an employee of Nihon Trim Co., Ltd.[11]. Nihon Trim manufactures water electrolysis equipment.
The 2025 canine kinetics study declares that its lead author has received advisory fees and research fees from Doctors Man Co., Ltd.[10].
None of this makes the results wrong. Device research is usually funded by device makers, and the papers disclosed it properly, which is how the system is supposed to work. It does mean the field lacks what would settle the question: a large, controlled, independently run trial from a group with no commercial interest in the answer.
The outcome nobody has measured
Every human study here has a surrogate endpoint. Blood pressure, inflammation markers, albumin redox state, methylguanidine, effluent CA125. Those are all reasonable things to measure in early work.
None of them is the outcome that matters to a dialysis patient. Nobody has run a trial powered to ask whether hydrogen-enriched dialysis changes mortality, cardiovascular events, hospitalisation, or how long someone can stay on peritoneal dialysis before the membrane fails. Until a trial like that exists, the honest position is that this is a plausible, well-tolerated idea with supportive surrogate data and no demonstrated clinical benefit.
The 2024 review’s own conclusion is phrased in exactly those terms: that the medical utility is believed to be substantial and that further investigation is warranted[11]. Believed and warranted are the operative words.
What this means if you or someone you know is on dialysis
Practically, nothing you can act on alone. Hydrogen-enriched dialysate requires the dialysis unit to install and run a hydrogen generation system feeding the water treatment plant. It is a decision made by a renal unit, not a patient, and outside Japan it is not standard equipment.
What is worth saying clearly is the reverse inference, because it is the one people actually make. Drinking hydrogen water is not a home version of this. The dialysis research delivers hydrogen directly into a blood circuit through a machine membrane during treatment, and even then most of it is cleared through the lungs before it circulates[10]. Nothing in these studies tested a tablet, a bottle or an oral dose, and nothing in them supports using one as kidney treatment.
Anyone with kidney disease considering any supplement should raise it with their nephrologist first, and that applies with particular force to hydrogen tablets, which are magnesium-based and therefore deliver a magnesium load to someone whose kidneys may not clear it normally.
The bottom line
Molecular hydrogen dissolved in dialysate has been studied in people for close to two decades. The strongest evidence is a 6-month uncontrolled trial in 21 patients showing improved blood pressure control and reduced inflammation markers[1], and an 8-patient crossover study showing reduced oxidative modification of albumin across the dialyzer[4].
It appears to be well tolerated. It has never been tested against a hard clinical outcome. Its main human trial had no control group, the literature is concentrated in a few industry-linked groups, and the most recent kinetics work suggests the effect is local to the machine rather than systemic[10].
It is a real area of medical research, and it is not a reason to buy anything.
References
- A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: a clinical trial. Nephrology Dialysis Transplantation, 2010
- Less-oxidative hemodialysis solution rendered by cathode-side application of electrolyzed water. Hemodialysis International, 2007
- Biological effects of electrolyzed water in hemodialysis. Nephron Clinical Practice, 2009
- Effect of a hydrogen (H2)-enriched solution on the albumin redox of hemodialysis patients. Hemodialysis International, 2014
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
- Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases. Oxidative Medicine and Cellular Longevity, 2012
- Dialysate with high dissolved hydrogen facilitates dissociation of indoxyl sulfate from albumin. Nephro-Urology Monthly, 2015
- Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity. BMC Nephrology, 2017
- Translational Research of Peritoneal Dialysis Solution with Dissolved Molecular Hydrogen. Contributions to Nephrology, 2018
- High-Concentration Hydrogen Delivery During Dialysis Using an Innovative Direct Dissolution Technique: In Vivo Kinetics in a Canine Model. ASAIO Journal, 2025
- Application of Electrolyzed Hydrogen Water for Management of Chronic Kidney Disease and Dialysis Treatment: Perspective View. Antioxidants, 2024
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.